SLGL vs. BIVI, TCRT, KALA, MEIP, SYBX, APM, GLTO, INDP, NRSN, and RNXT
Should you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include BioVie (BIVI), Alaunos Therapeutics (TCRT), KALA BIO (KALA), MEI Pharma (MEIP), Synlogic (SYBX), Aptorum Group (APM), Galecto (GLTO), Indaptus Therapeutics (INDP), NeuroSense Therapeutics (NRSN), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical preparations" industry.
Sol-Gel Technologies (NASDAQ:SLGL) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment.
In the previous week, BioVie had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 1 mentions for BioVie and 0 mentions for Sol-Gel Technologies. BioVie's average media sentiment score of 0.47 beat Sol-Gel Technologies' score of 0.00 indicating that BioVie is being referred to more favorably in the news media.
Sol-Gel Technologies currently has a consensus price target of $8.00, indicating a potential upside of 998.60%. BioVie has a consensus price target of $8.00, indicating a potential upside of 1,548.46%. Given BioVie's higher probable upside, analysts plainly believe BioVie is more favorable than Sol-Gel Technologies.
Sol-Gel Technologies has higher revenue and earnings than BioVie. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.
BioVie has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -1,331.01%. Sol-Gel Technologies' return on equity of -61.52% beat BioVie's return on equity.
Sol-Gel Technologies has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
Sol-Gel Technologies received 131 more outperform votes than BioVie when rated by MarketBeat users. However, 64.00% of users gave BioVie an outperform vote while only 63.09% of users gave Sol-Gel Technologies an outperform vote.
26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 4.8% of BioVie shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Sol-Gel Technologies beats BioVie on 11 of the 17 factors compared between the two stocks.
Get Sol-Gel Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sol-Gel Technologies Competitors List
Related Companies and Tools
